Literature DB >> 7936651

A germline 2.35 kb deletion of p53 genomic DNA creating a specific loss of the oligomerization domain inherited in a Li-Fraumeni syndrome family.

S J Plummer1, M Santibáñez-Koref, T Kurosaki, S Liao, B Noble, P R Fain, H Anton-Culver, G Casey.   

Abstract

The primary genetic cancer predisposing event in many Li-Fraumeni syndrome families is a germline mutation in the p53 gene. We describe an extended Li-Fraumeni family with a germline mutation in the p53 gene involving a deletion of exon 10. The mutation is a 2.35 kilobase intragenic deletion encompassing exon 10, which results in the specific loss of the entire p53 oligomerization domain. This mutation segregates with the cancer phenotype. A lymphoblastoid cell line developed from a mutation carrier shows accumulation of mutant p53 protein by immunoblotting. However, tumor tissues from two affected carriers are negative by immunohistochemical staining. A major structural alteration specifically involving the oligomerization domain of a germline p53 gene has not been previously described and occurs in a region rarely mutated in sporadic tumors. The oligomerization domain is dispensable for many wild-type p53 functions, including transactivation, sequence-specific DNA binding, and suppression of oncogenic transformation. However, the domain appears to be required for transcriptional repression, and DNA strand reassociation. The identification of this mutation in an LFS family may yield insights into the importance of the oligomerization domain for suppressor function of the p53 tumor suppressor gene.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7936651

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  9 in total

1.  A common molecular mechanism underlies two phenotypically distinct 17p13.1 microdeletion syndromes.

Authors:  Adam Shlien; Berivan Baskin; Maria Isabel W Achatz; Dimitrios J Stavropoulos; Kim E Nichols; Louanne Hudgins; Chantal F Morel; Margaret P Adam; Nataliya Zhukova; Lianne Rotin; Ana Novokmet; Harriet Druker; Mary Shago; Peter N Ray; Pierre Hainaut; David Malkin
Journal:  Am J Hum Genet       Date:  2010-11-12       Impact factor: 11.025

Review 2.  Genotype phenotype correlation in Li-Fraumeni syndrome kindreds and its implications for management.

Authors:  R N Moule; S G Jhavar; R A Eeles
Journal:  Fam Cancer       Date:  2006       Impact factor: 2.375

Review 3.  Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others.

Authors:  Kanaga Sabapathy; David P Lane
Journal:  Nat Rev Clin Oncol       Date:  2017-09-26       Impact factor: 66.675

4.  The C-terminal domain of p53 recognizes DNA damaged by ionizing radiation.

Authors:  M Reed; B Woelker; P Wang; Y Wang; M E Anderson; P Tegtmeyer
Journal:  Proc Natl Acad Sci U S A       Date:  1995-10-10       Impact factor: 11.205

Review 5.  Tumors associated with p53 germline mutations: a synopsis of 91 families.

Authors:  P Kleihues; B Schäuble; A zur Hausen; J Estève; H Ohgaki
Journal:  Am J Pathol       Date:  1997-01       Impact factor: 4.307

Review 6.  Li-Fraumeni syndrome--a molecular and clinical review.

Authors:  J M Varley; D G Evans; J M Birch
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

7.  TP53 Pathogenic Variants in Early-Onset Breast Cancer Patients Fulfilling Hereditary Breast and Ovary Cancer and Li-Fraumeni-like Syndromes.

Authors:  Paula Francinete Faustino da Silva; Rebeca Mota Goveia; Thaís Bomfim Teixeira; Bruno Faulin Gamba; Aliny Pereira de Lima; Sílvia Regina Rogatto; Elisângela de Paula Silveira-Lacerda
Journal:  Biomolecules       Date:  2022-04-27

8.  Regional analysis of p53 mutations in rheumatoid arthritis synovium.

Authors:  Yuji Yamanishi; David L Boyle; Sanna Rosengren; Douglas R Green; Nathan J Zvaifler; Gary S Firestein
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-15       Impact factor: 11.205

Review 9.  Genetically Engineered Pigs to Study Cancer.

Authors:  Daniela Kalla; Alexander Kind; Angelika Schnieke
Journal:  Int J Mol Sci       Date:  2020-01-13       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.